The Fort Worth Press - Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

USD -
AED 3.672499
AFN 63.000213
ALL 83.045552
AMD 377.608336
ANG 1.790083
AOA 916.99993
ARS 1391.475899
AUD 1.436555
AWG 1.8025
AZN 1.702097
BAM 1.692703
BBD 2.017085
BDT 122.889314
BGN 1.709309
BHD 0.377678
BIF 2964.437482
BMD 1
BND 1.280822
BOB 6.920277
BRL 5.343438
BSD 1.001532
BTN 93.628346
BWP 13.656801
BYN 3.038457
BYR 19600
BZD 2.014228
CAD 1.37385
CDF 2274.999924
CHF 0.791335
CLF 0.023505
CLP 928.093911
CNY 6.886396
CNH 6.91253
COP 3696.54
CRC 467.791212
CUC 1
CUP 26.5
CVE 95.432004
CZK 21.28799
DJF 178.340531
DKK 6.48348
DOP 59.449729
DZD 132.432632
EGP 52.233671
ERN 15
ETB 157.836062
EUR 0.86771
FJD 2.227199
FKP 0.749521
GBP 0.751565
GEL 2.714963
GGP 0.749521
GHS 10.917148
GIP 0.749521
GMD 73.497588
GNF 8778.549977
GTQ 7.671603
GYD 209.529662
HKD 7.828115
HNL 26.509205
HRK 6.533006
HTG 131.388314
HUF 342.017982
IDR 16993
ILS 3.139598
IMP 0.749521
INR 93.938501
IQD 1311.97909
IRR 1315625.000003
ISK 124.779797
JEP 0.749521
JMD 157.346743
JOD 0.708989
JPY 159.455972
KES 129.598158
KGS 87.4479
KHR 4001.973291
KMF 427.000057
KPW 900.003974
KRW 1512.965024
KWD 0.30679
KYD 0.834581
KZT 481.491739
LAK 21506.092917
LBP 89692.06536
LKR 312.41778
LRD 183.27376
LSL 16.894603
LTL 2.95274
LVL 0.60489
LYD 6.411466
MAD 9.358386
MDL 17.440975
MGA 4176.061001
MKD 53.425388
MMK 2099.452431
MNT 3566.950214
MOP 8.084003
MRU 40.089837
MUR 46.570151
MVR 15.46035
MWK 1736.722073
MXN 18.02175
MYR 3.939504
MZN 63.899678
NAD 16.894749
NGN 1362.960126
NIO 36.852081
NOK 9.669101
NPR 149.804404
NZD 1.726235
OMR 0.384479
PAB 1.001519
PEN 3.46252
PGK 4.323066
PHP 60.289868
PKR 279.628351
PLN 3.71807
PYG 6541.287659
QAR 3.662273
RON 4.422399
RSD 101.958019
RUB 82.166009
RWF 1457.231632
SAR 3.754935
SBD 8.05166
SCR 13.925407
SDG 600.999925
SEK 9.43335
SGD 1.28433
SHP 0.750259
SLE 24.574953
SLL 20969.510825
SOS 572.35094
SRD 37.487497
STD 20697.981008
STN 21.204227
SVC 8.762971
SYP 110.564047
SZL 16.900787
THB 32.947502
TJS 9.619362
TMT 3.51
TND 2.95786
TOP 2.40776
TRY 44.330501
TTD 6.794814
TWD 32.098502
TZS 2594.999914
UAH 43.875212
UGX 3785.603628
UYU 40.356396
UZS 12210.172836
VES 454.69063
VND 26341
VUV 119.226095
WST 2.727792
XAF 567.726608
XAG 0.015629
XAU 0.000235
XCD 2.70255
XCG 1.80494
XDR 0.706079
XOF 567.716781
XPF 103.216984
YER 238.601849
ZAR 17.185098
ZMK 9001.201832
ZMW 19.554625
ZWL 321.999592
  • RIO

    -2.5000

    83.15

    -3.01%

  • BCE

    0.0600

    25.79

    +0.23%

  • CMSC

    -0.2000

    22.65

    -0.88%

  • BCC

    -1.5600

    68.3

    -2.28%

  • RBGPF

    -13.5000

    69

    -19.57%

  • CMSD

    -0.2420

    22.658

    -1.07%

  • BTI

    -1.3500

    57.37

    -2.35%

  • RYCEF

    -1.2600

    15.34

    -8.21%

  • NGG

    -3.5400

    81.99

    -4.32%

  • GSK

    -0.5300

    51.84

    -1.02%

  • JRI

    -0.3900

    11.77

    -3.31%

  • AZN

    -5.3300

    183.6

    -2.9%

  • BP

    -1.0800

    44.78

    -2.41%

  • RELX

    -0.4600

    33.36

    -1.38%

  • VOD

    -0.0900

    14.33

    -0.63%

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts
Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, March 12, 2026 at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com.

Text size:

Participation Instructions for Jaguar's Virtual Presentation at the Life Sciences Investor Forum

When: Thursday, March 12, 2026 at 2:00 PM Eastern

Registration link for conference: Click Here

Replay: A replay of the webcast will be available following the conclusion of the conference.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that Jaguar management will present at the March 2026 conference listed above. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

[email protected]

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.



View the original press release on ACCESS Newswire

X.Silva--TFWP